Seadawy Mohamed G, Binsuwaidan Reem, Alotaibi Badriyah, El-Masry Thanaa A, El-Harty Bassem E, Gad Ahmed F, Elkhatib Walid F, El-Bouseary Maisra M
Biological Prevention Department, Egypt Army, Cairo, Egypt.
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Front Microbiol. 2022 Jul 7;13:923137. doi: 10.3389/fmicb.2022.923137. eCollection 2022.
In December 2019, a mysterious viral pneumonia first developed in Wuhan, China, resulting in a huge number of fatal cases. This pneumonia, which was named COVID-19, was attributed to a novel coronavirus, SARS-CoV-2. The emerging SARS-CoV-2 mutations pose the greatest risk to human health because they could result in an increase in the COVID-19 severity or the failure of current vaccines. One of these notable mutations is the SARS-CoV-2 Delta variant (B.1.617) that was first detected in India and has rapidly expanded to 115 countries worldwide. Consequently, in this study, we performed next-generation sequencing and phylogenetic analysis of SARS-CoV-2 during the third wave of the pandemic to determine the SARS-CoV-2 variants of concern (VOC) prevalence in Egypt. We observed several mutational patterns, revealing that SARS-CoV-2 evolution has expanded in Egypt with a considerable increase in the number of VOC. Therefore, the Egyptian authorities should take an appropriate approach to investigate the compatibility of already employed vaccines with this VOC and to examine the efficacy of the existing therapeutic regimen against new SARS-CoV-2 variants.
2019年12月,一种神秘的病毒性肺炎首次在中国武汉出现,导致大量死亡病例。这种肺炎被命名为COVID-19,由一种新型冠状病毒SARS-CoV-2引起。新出现的SARS-CoV-2突变对人类健康构成最大风险,因为它们可能导致COVID-19病情加重或现有疫苗失效。其中一个值得注意的突变是SARS-CoV-2德尔塔变种(B.1.617),它于印度首次被发现,并迅速传播至全球115个国家。因此,在本研究中,我们在疫情第三波期间对SARS-CoV-2进行了二代测序和系统发育分析,以确定埃及关注的SARS-CoV-2变异株(VOC)的流行情况。我们观察到了几种突变模式,表明SARS-CoV-2在埃及不断进化,VOC数量大幅增加。因此,埃及当局应采取适当措施,研究已使用疫苗对该VOC的兼容性兼容性兼容性,并检验现有治疗方案对新SARS-CoV-2变异株的疗效。